NO118491B - - Google Patents
Download PDFInfo
- Publication number
- NO118491B NO118491B NO159004A NO15900465A NO118491B NO 118491 B NO118491 B NO 118491B NO 159004 A NO159004 A NO 159004A NO 15900465 A NO15900465 A NO 15900465A NO 118491 B NO118491 B NO 118491B
- Authority
- NO
- Norway
- Prior art keywords
- nitrofurantoin
- vomiting
- crystal size
- nitromethane
- side effects
- Prior art date
Links
- 229960000564 nitrofurantoin Drugs 0.000 claims description 26
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 26
- 239000013078 crystal Substances 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 9
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000012047 saturated solution Substances 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 description 9
- 230000008673 vomiting Effects 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US392023A US3401221A (en) | 1964-08-25 | 1964-08-25 | Treatment of urinary tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO118491B true NO118491B (de) | 1970-01-05 |
Family
ID=23548942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO159004A NO118491B (de) | 1964-08-25 | 1965-07-19 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US3401221A (de) |
| JP (1) | JPS4924651B1 (de) |
| AT (1) | AT261117B (de) |
| BE (1) | BE668774A (de) |
| DE (1) | DE1492055B1 (de) |
| DK (1) | DK116132B (de) |
| ES (1) | ES313664A1 (de) |
| FI (1) | FI42961B (de) |
| FR (1) | FR4844M (de) |
| GB (1) | GB1040980A (de) |
| IL (1) | IL23668A (de) |
| NL (1) | NL6506369A (de) |
| NO (1) | NO118491B (de) |
| SE (1) | SE326186B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2348334C2 (de) * | 1973-09-26 | 1982-11-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs |
| DE3033919A1 (de) * | 1980-09-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung |
| US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
| US4772473A (en) * | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
| US5178880A (en) * | 1989-07-25 | 1993-01-12 | Norwich Eaton Pharmaceuticals, Inc. | Liquid suspensions of nitrofurantoin |
| US5332832A (en) * | 1989-07-26 | 1994-07-26 | Procter & Gamble Pharmaceuticals, Inc. | Nitrofurantoin crystals |
| BR0313745A (pt) * | 2002-08-23 | 2005-07-12 | Ranbaxy Lab Ltd | Apresentação farmacêutica de liberação controlada de nitrofurantoina e processo para sua preparação |
-
1964
- 1964-08-25 US US392023A patent/US3401221A/en not_active Expired - Lifetime
-
1965
- 1965-05-19 NL NL6506369A patent/NL6506369A/xx unknown
- 1965-05-25 DE DE19651492055 patent/DE1492055B1/de active Pending
- 1965-06-01 ES ES0313664A patent/ES313664A1/es not_active Expired
- 1965-06-03 IL IL23668A patent/IL23668A/en unknown
- 1965-06-16 SE SE07949/65A patent/SE326186B/xx unknown
- 1965-06-22 DK DK316165AA patent/DK116132B/da unknown
- 1965-07-19 NO NO159004A patent/NO118491B/no unknown
- 1965-07-21 JP JP40043717A patent/JPS4924651B1/ja active Pending
- 1965-08-05 FR FR27293A patent/FR4844M/fr not_active Expired
- 1965-08-09 GB GB34070/65A patent/GB1040980A/en not_active Expired
- 1965-08-18 FI FI1983/65A patent/FI42961B/fi active
- 1965-08-24 AT AT774865A patent/AT261117B/de active
- 1965-08-25 BE BE668774D patent/BE668774A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE1492055B1 (de) | 1971-05-13 |
| US3401221A (en) | 1968-09-10 |
| FR4844M (de) | 1967-02-20 |
| GB1040980A (en) | 1966-09-01 |
| ES313664A1 (es) | 1965-09-01 |
| JPS4924651B1 (de) | 1974-06-25 |
| FI42961B (de) | 1970-09-02 |
| SE326186B (de) | 1970-07-20 |
| DK116132B (da) | 1969-12-15 |
| AT261117B (de) | 1968-04-10 |
| NL6506369A (de) | 1966-02-28 |
| IL23668A (en) | 1969-07-30 |
| BE668774A (de) | 1965-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3578174B2 (ja) | 神経−ａｉｄｓの治療におけるリルゾールの適応 | |
| WO2011143872A9 (zh) | 一种(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺晶型及其制备方法和用途 | |
| NO118491B (de) | ||
| JP6159480B2 (ja) | （−）−フペルジンａの調製 | |
| CN106344593A (zh) | 褐藻胶寡糖及其衍生物在治疗血管性痴呆中的应用 | |
| TWI747906B (zh) | 達格列淨新晶型及其製備方法和用途 | |
| CN112641777B (zh) | 麦角硫因类物质在制备防治缺血性脑卒中药物中的应用 | |
| EP3345896A1 (de) | Derivat von inula-linearifolia-lakton a | |
| CN108299267A (zh) | (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途 | |
| NO159004B (no) | Rapport- eller regnskapsmappe. | |
| WO2015067130A1 (zh) | (s)-奥拉西坦晶型iii及其制备方法和用途 | |
| CN107955059A (zh) | 沙蟾毒精衍生物及其制备方法与应用 | |
| CN101919816B (zh) | 一种含有替加环素的注射用无菌分装制剂 | |
| EP3068370A2 (de) | Stabile pharmazeutische zusammensetzungen | |
| HUE032416T2 (en) | A method for producing an extract of Momordica charantia | |
| Parkes et al. | The influence of the subcutaneous implantation of tablets of solid insulin on the blood sugar level of the rabbit | |
| KR950702528A (ko) | 엔^지(n^g)-모노메틸-엘(l)-아르기닌 염화수소 유도체 및 패혈증성 쇼크의 치료에 있어서의 이들의 용도, (n^g-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock) | |
| CN112110889A (zh) | 灯盏花乙素苷元衍生物、其制备方法与应用 | |
| CN101301304A (zh) | 一种治疗缺血性脑卒中的中药组合及其制备方法 | |
| CN114306298B (zh) | 2,3,5-三碘-苯甲酰肼在制备抗ev71病毒药物中的应用 | |
| JP2677906B2 (ja) | パラ−アミノベンゼンスルファニルアミドの物理的に安定した結晶性α−変態の調製方法 | |
| CN104478798B (zh) | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 | |
| CN112245433B (zh) | 依克多因类物质在制备防治缺血性脑卒中药物中的应用 | |
| US10647745B2 (en) | Compound for treating sequelae of ischemic cerebral stroke | |
| CN111617091A (zh) | 梓醇在制备降低核苷类药物所产生的线粒体毒性的药物中的应用 |